ArticleJournal of the National Cancer Institute2012
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.
Article in Journal of the National Cancer Institute, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 3 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity.American journal of epidemiology · 2017Pooled it
- CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.Clinical pharmacology and therapeutics · 2014Pooled it
- Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy.Future oncology (London, England) · 2014Pooled it
- Clinical and pharmacogenomic predictors of survival in tamoxifen treated breast cancer female patients: a real-world study.BMC cancer · 2025Article
- ClinicalCancers · 2021Review
- CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study.Breast cancer research : BCR · 2018Article
- Cytochrome P450 Genetic Variation Associated with Tamoxifen Biotransformation in American Indian and Alaska Native People.Clinical and translational science · 2018Article
- Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.Journal of the National Cancer Institute · 2014Article
- Re: Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA.Journal of the National Cancer Institute · 2014Article
- Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer.British journal of clinical pharmacology · 2014Article
- Status of adjuvant endocrine therapy for breast cancer.Breast cancer research : BCR · 2014Review
- PharmGKB summary: tamoxifen pathway, pharmacokinetics.Pharmacogenetics and genomics · 2013Review
- Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA.Journal of the National Cancer Institute · 2013Article
- Pharmacogenomics of breast cancer therapy: an update.Pharmacology & therapeutics · 2013Review
- Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2013Article
- Variants in tamoxifen metabolizing genes: a case-control study of contralateral breast cancer risk in the WECARE study.International journal of molecular epidemiology and genetics · 2013Article
- Trends in co-prescribing of antidepressants and tamoxifen among women with breast cancer, 2004-2010.Breast cancer research and treatment · 2013Article
Corrections and comments
- Comment on
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.